Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cushing disease

- PMLiVE

FDA approves Allergan’s biodegradable glaucoma implant drug

Reduces intraocular pressure in glaucoma or ocular hypertension

- PMLiVE

Trevena gets second go at FDA approval for pain drug

FDA sets review completion date of 7 August 2020

- PMLiVE

Biohaven gets FDA approval for migraine drug Nurtec ODT

Becomes second drugmaker to bring an oral CGRP inhibitor to US market

- PMLiVE

Raising awareness and encouraging support on Rare Disease Day 2020

Rare Disease Day takes place on 29 February around the world

- PMLiVE

Acacia finally gets FDA okay for first product Barhemsys

Edison analyst predicts drug could reach $387m at peak

- PMLiVE

Lilly’s Cyramza narrowly clears FDA adcomm vote for first-line NSCLC

Advisory committee voted 6-5 in favour of drug

- PMLiVE

Coronavirus outbreak escalation could impact drug supply chain

Concerns raised that the virus could cause shortages

- PMLiVE

Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA

Final decision due by 18 October

- PMLiVE

Esperion gets FDA thumbs up for cholesterol drug Nexletol

Big comeback after previous trial fail

EISAI

Eisai agrees to pull obesity drug Belviq after safety alert

Weight-loss drug linked to increased risk of cancer

- PMLiVE

FDA accepts priority review for Merck’s antibiotic combo Recarbrio

If approved would provide new option for hard-to-treat infections

Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603

Blueberry Therapeutics has received an investigational new drug (IND) clearance from the Food and Drug Administration (FDA) to proceed with the clinical development of BB2603

Onyx Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links